Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report), Hologic (HOLX – Research Report) and Bicycle Therapeutics (BCYC – Research Report).
Tilray (TLRY)
In a report released today, William Kirk from Roth MKM reiterated a Hold rating on Tilray, with a price target of $2.00. The company’s shares closed last Tuesday at $2.06.
According to TipRanks.com, Kirk ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Tilray is a Hold with an average price target of $2.58, which is a 21.7% upside from current levels. In a report issued on April 5, Alliance Global Partners also maintained a Hold rating on the stock with a $2.75 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bicycle Therapeutics (BCYC)
In a report released today, Ami Fadia from Needham maintained a Buy rating on Bicycle Therapeutics, with a price target of $43.00. The company’s shares closed last Tuesday at $23.07.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
Bicycle Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.71, implying a 93.8% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $32.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TLRY:
- Tilray Reported Earnings. Did it Beat Estimates?
- TLRY Earnings: Tilray Brands Plunges on Weak Guidance
- Options Volatility and Implied Earnings Moves Today, April 09, 2024
- Unusually active option classes on open April 8th
- Options Volatility and Implied Earnings Moves This Week, April 08 – April 12, 2024
